Opioid Overdose Treatment Market Expected to Hit $3.1 Billion by 2034, Says Fact.MR Report

According to a recent industry analysis by skilled researchers at Fact.MR, a market research and competitive intelligence provider, the global opioid overdose treatment market is anticipated to reach a value of US$ 1.54 billion in 2024. Through 2034, market revenue is expected to grow at a compound annual growth rate (CAGR) of 7.2%.

Because of its detrimental effects on the human brain, an excessive opioid overdose can be fatal. It has an adverse effect on respiratory regulation. Other symptoms that are seen and aid in identifying opioid overdose include pinpoint pupils and unconsciousness. People with chronic pain are experiencing an increasing number of opioid overdose occurrences. Drugs like opioid agonists and antagonists can save lives when administered on time.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=10246

Key Insights from the Opioid Overdose Treatment Market

• North America dominates the global opioid overdose treatment market, accounting for over 40% of total revenue, with the United States holding a significant regional share.
• The global market is expected to reach $3.1 billion by 2034.
• Opioid antagonists are forecasted to represent 3% of global market revenue by the end of the forecast period.
• Naloxone is projected to hold a 36% share of the global market by 2034.
• Worldwide demand for prescription-based treatments is anticipated to grow at a 2% CAGR, reaching a market value of $2.71 billion by 2034.
• East Asia is predicted to account for 7% of global revenue by the end of 2034.
• In South Korea, demand for opioid overdose treatments is expected to grow at a robust 8% CAGR from 2024 to 2034.
• The market in India is projected to expand at a 2% CAGR over the same period.

Key Players Fueling Innovation in the Market for Opioid Overdose Treatment:

Amneal Pharmaceuticals, Astellas Pharma, AstraZeneca, Bayer, Biotoscana, Collegium Pharmaceutical, EMS Pharma, Endo International, Ethypharm, Eurofarma, GlaxoSmithKline, Hikma Pharmaceuticals, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mundipharma, Mylan, Novartis, Pfizer, Purdue Pharma, Sanofi, Stada Arzneimittel, Takeda, and Teva Pharmaceuticals are a few of the top companies that treat opioid overdose.

Rising Demand for Opioid Antagonists in Overdose Treatment

The global demand for opioid antagonists is anticipated to grow at a CAGR of 7.8%, reaching a market value of $1.06 billion by 2034. This increasing popularity is driven by their proven effectiveness in counteracting the effects of commonly used opioids, including naltrexone. Additionally, their role in managing opioid overdoses and treating alcohol use disorders is creating lucrative opportunities for market participants worldwide.

News from the Opioid Overdose Treatment Industry:

In order to enhance results, major participants in the opioid overdose treatment sector are concentrating on creating more sophisticated and efficient solutions.

For instance, Amneal's Naloxone HCI Nasal Spray became a popular therapy for opioid drug overdoses after receiving FDA clearance in April 2024.

Why is the market for opioid overdose treatment growing so quickly?

When opioids negatively impact the area of the human brain that controls breathing, an opioid overdose can happen in conjunction with a number of other drugs, including sedatives, alcohol, or stimulants. Symptoms of an opioid overdose include bluish lips, gurgling or snoring sounds from the mouth, pinpoint pupils, cold or clammy skin, shallowness, stopped or delayed breathing, and unconsciousness or unresponsiveness. These problems result in inefficient breathing and, in extreme situations, even death. Naloxone and prompt medical attention are necessary for an individual who has overdosed on opioids in order to avoid serious health consequences.

Country-specific Perspectives

According to this recently released study by market research and competitive intelligence firm Fact.MR, North America is expected to account for 43.9% of the global market share for opioid overdose therapy by the end of 2034. The region's high demand for opioid overdose treatment options is caused by an increase in chronic pain and mental health issues, which fuel opioid use. The majority of people with chronic illnesses are between the ages of 18 and 45, which is creating lucrative potential for companies that offer opioid overdose treatment solutions.

By the end of 2034, the United States is expected to hold an 85% market share in North America.

• A report titled "Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths – United States, 2023-2019", published by the Morbidity and Mortality Weekly Report on February 12, 2021, revealed that 70,630 individuals in the United States died from drug overdoses in 2019, with nearly half of these deaths linked to synthetic opioids.

The growing prevalence of opioid overdose highlights the urgent need for effective treatment solutions to save lives and address this escalating crisis.

Category-Specific Perspectives

By the end of 2034, the global market for prescription-based opioid overdose treatment solutions is expected to be valued at US$ 2.71 billion, with a compound annual growth rate (CAGR) of 7.2%. These sales channels are becoming more and more popular because of the meds' safety, reliability, and genuineness.

By 2034, the opioid antagonist medication class is expected to hold a 34.3% market share worldwide. These medications, of which naltrexone is a very frequent one, are used to counteract the effects of some common opioids. They aid in the management of overdoses caused by opioids. Additionally, its support in treating alcohol disorders, opioid-induced constipation, and opioid use disorders is driving up demand among medical professionals worldwide.

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com